1. Home
  2. LEGN vs LOPE Comparison

LEGN vs LOPE Comparison

Compare LEGN & LOPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • LOPE
  • Stock Information
  • Founded
  • LEGN 2014
  • LOPE 1949
  • Country
  • LEGN United States
  • LOPE United States
  • Employees
  • LEGN N/A
  • LOPE N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • LOPE Other Consumer Services
  • Sector
  • LEGN Health Care
  • LOPE Real Estate
  • Exchange
  • LEGN Nasdaq
  • LOPE Nasdaq
  • Market Cap
  • LEGN 5.4B
  • LOPE 5.2B
  • IPO Year
  • LEGN 2020
  • LOPE 2008
  • Fundamental
  • Price
  • LEGN $35.56
  • LOPE $203.39
  • Analyst Decision
  • LEGN Strong Buy
  • LOPE Buy
  • Analyst Count
  • LEGN 10
  • LOPE 3
  • Target Price
  • LEGN $73.67
  • LOPE $203.67
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • LOPE 327.3K
  • Earning Date
  • LEGN 08-11-2025
  • LOPE 08-06-2025
  • Dividend Yield
  • LEGN N/A
  • LOPE N/A
  • EPS Growth
  • LEGN N/A
  • LOPE 11.89
  • EPS
  • LEGN N/A
  • LOPE 8.26
  • Revenue
  • LEGN $796,838,000.00
  • LOPE $1,067,673,000.00
  • Revenue This Year
  • LEGN $66.76
  • LOPE $7.84
  • Revenue Next Year
  • LEGN $52.58
  • LOPE $6.73
  • P/E Ratio
  • LEGN N/A
  • LOPE $24.62
  • Revenue Growth
  • LEGN 74.75
  • LOPE 6.52
  • 52 Week Low
  • LEGN $27.34
  • LOPE $130.69
  • 52 Week High
  • LEGN $59.62
  • LOPE $206.76
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 35.54
  • LOPE 70.44
  • Support Level
  • LEGN $35.10
  • LOPE $197.12
  • Resistance Level
  • LEGN $38.35
  • LOPE $198.97
  • Average True Range (ATR)
  • LEGN 1.31
  • LOPE 5.81
  • MACD
  • LEGN -0.37
  • LOPE 1.90
  • Stochastic Oscillator
  • LEGN 11.33
  • LOPE 90.72

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About LOPE Grand Canyon Education Inc.

Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.

Share on Social Networks: